NO130048B - - Google Patents
Download PDFInfo
- Publication number
- NO130048B NO130048B NO04610/71*[A NO461071A NO130048B NO 130048 B NO130048 B NO 130048B NO 461071 A NO461071 A NO 461071A NO 130048 B NO130048 B NO 130048B
- Authority
- NO
- Norway
- Prior art keywords
- machine according
- concrete
- feeding belt
- wall
- container
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 2
- 238000005056 compaction Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 238000009751 slip forming Methods 0.000 claims 1
- SPJMAPNWDLIVRR-UHFFFAOYSA-M sodium;3-chloro-2-phenylphenolate Chemical compound [Na+].[O-]C1=CC=CC(Cl)=C1C1=CC=CC=C1 SPJMAPNWDLIVRR-UHFFFAOYSA-M 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 14
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 235000019256 formaldehyde Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000001882 diuretic effect Effects 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- -1 alkali metal salts Chemical class 0.000 description 5
- IHJCXVZDYSXXFT-UHFFFAOYSA-N chloraminophenamide Chemical compound NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O IHJCXVZDYSXXFT-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960002155 chlorothiazide Drugs 0.000 description 4
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 230000001452 natriuretic effect Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000000571 coke Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JVMPQYRPGCRZQH-UHFFFAOYSA-N 3-pentyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2NC(CCCCC)=NS(=O)(=O)C2=C1 JVMPQYRPGCRZQH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical class Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B28—WORKING CEMENT, CLAY, OR STONE
- B28B—SHAPING CLAY OR OTHER CERAMIC COMPOSITIONS; SHAPING SLAG; SHAPING MIXTURES CONTAINING CEMENTITIOUS MATERIAL, e.g. PLASTER
- B28B1/00—Producing shaped prefabricated articles from the material
- B28B1/08—Producing shaped prefabricated articles from the material by vibrating or jolting
- B28B1/084—Producing shaped prefabricated articles from the material by vibrating or jolting the vibrating moulds or cores being moved horizontally for making strands of moulded articles
Landscapes
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Chemical & Material Sciences (AREA)
- Ceramic Engineering (AREA)
- Mechanical Engineering (AREA)
- Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
- On-Site Construction Work That Accompanies The Preparation And Application Of Concrete (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Press-Shaping Or Shaping Using Conveyers (AREA)
- Manufacturing Of Tubular Articles Or Embedded Moulded Articles (AREA)
Description
Fremgangsmåte til fremstilling av 6-klor-7-sulfamyl-3,4-dihydro- 1, 2, 4- benzo-tiadiazin-l,l-dioksyd, som har diuretisk og natriuretisk virkning. Process for the production of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzo-thiadiazine-1,1-dioxide, which has diuretic and natriuretic action.
Gjenstanden for foreliggende oppfin-nelse er fremstilling av 6-klor-7-sulfamyl-3,4-dihydro-l,2,4-benzotiadiazin-l,l-dioksyd med formelen: The object of the present invention is the production of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide with the formula:
og dens salter, særlig med alkallmetaller. Denne forbindelse viser en fremragende diuretisk og natriuretisk virkning. Dette fremgår av sammenliknende forsøk med det i handelen tilgjengelige klorotiazid (6 -klor-7 -sulf amyl-1,2,4-benzotiadiazin-1,1-dioksyd). Akutte forsøk av 6 timers va-righet hos hund viser følgende resultater, idet den nye forbindelse ble gitt betegnel-sen SU-5879. and its salts, especially with alkali metals. This compound shows an outstanding diuretic and natriuretic effect. This is evident from comparative experiments with the commercially available chlorothiazide (6-chloro-7-sulfa amyl-1,2,4-benzothiadiazine-1,1-dioxide). Acute tests lasting 6 hours in dogs show the following results, the new compound being given the designation SU-5879.
Gjennomsnittsverdi av forsøk på 7 hunder. Average value of trials of 7 dogs.
Fra denne tabell fremgår det at den diuretiske virkning for den nye forbindelse From this table it appears that the diuretic effect of the new compound
hos hund, er vesentlig bedre enn virknin-gen av klorotiazid. in dogs, is significantly better than the effect of chlorothiazide.
Ved en videre sammenlikning av den diuretiske virkning for iden nye forbindelse In a further comparison of the diuretic effect for the new compound
med klorotiazid fikk rotter som ikke hadde with chlorothiazide received rats that had not
fått næring på 18 timer 0,2 pst.ig na-; received nutrition in 18 hours 0.2 pst.ig na-;
triumkloridoppløsning i en mengde som'triium chloride solution in an amount which'
tilsvarte 5 pst. av deres legemsvekt. Umid-delbart deretter ble disse gitt oralt hver corresponded to 5 percent of their body weight. Immediately thereafter, these were each given orally
en av disse forbindelser oppløst i 0,1 cm<3>one of these compounds dissolved in 0.1 cm<3>
fortynnet natronlut. Den spontant ut-tømte urin ble oppsamlet i graderte sylin-j diluted caustic soda. The spontaneously voided urine was collected in graduated cylinders
dere i løpet av de neste 3 .timer, volumet ble målt og omregnet i pst. av væsketil-førselen. Konsentrasjonen av natrium og you during the next 3 hours, the volume was measured and converted into percent of the fluid supply. The concentration of sodium and
■kalium ble bestemt flarnmefotometrisk og totalutskillelsen av disse elektrolytter ble ■potassium was determined flarnmephotometrically and the total excretion of these electrolytes was
.beregnet for den 3 timers forsøksperiode. De verdier som er sammenfattet i følgende tabell er gjennomsnittsverdier for 8—12 rotter pr. gruppe. .calculated for the 3 hour trial period. The values summarized in the following table are average values for 8-12 rats per group.
Av disse forsøk fremgår at den nye med omtrent ekvivalente mengder av reak-forbindelse virker sterkere på rotter enn sjonskomponentene. Ved høyere mengder klorotiazid. av aldehyd minskes utbyttene på grunn From these experiments it appears that the new one with approximately equivalent amounts of reaction compound works more strongly on rats than the reaction components. At higher amounts of chlorothiazide. of aldehyde, the yields are reduced due to
Den nye forbindelse har også ved an- av en reaksjon med sulfamylgruppen i 4-vendelse hos mennesker en sterk diuretisk stilling. Reaksjonen kan utføres i fravær qg natriuretisk virkning, mens kaliumut- eller fortrinnsvis i nærvær av oppløsnings-skiilingen ikke befordres i samme grad. Hos midler, slik som en eter, f. eks. paradioksan pasienter med væske- og koksaltretensjon eller dietylenglykoldimetyleter, eller et for-på grunn av sykdommer i hjerte, lever (ci- mamid, f. eks. dimetylformamid, ved rom-rose) eller nyrene (nefrose), bevirker for- temperatur eller forhøyet temperatur, og bindelsen en terapeutisk ønsket befordring ved normalt eller forhøyet trykk, eller i av væske- og koksaltutskillingen uten at nærvær av en inert gass, slik som nitrogen, det' samtidig består noen fare for en ka- Alt etter reaksjonsbetingelsene får liumuttapning. De doser som er nødven- man den nye forbindelse i fri form eller dige for en slik virkning ved peroral ad- i form av sine salter. Erholdte metallsalter ministrasjon ligger gjennomsnittlig på mel- kan f. eks. overføres til den fri forbindelse lom 25 og 100 mg pr. dag. Den nye forbin- ved reaksjon med vandige, sure midler, slik deise er også i stand til å senke det arteri- som mineralsyre, f. eks. halogenhydrogen-elle høye trykk, fremfor alt når det gis syre, f. eks. saltsyre eller svovelsyre. Disse samtidig med annet blodtrykksenkende kan igjen overføres til metallsaltene, slik middel. som alkalimetallsalter ved behandling f. The new compound also has a strong diuretic effect in humans through a reaction with the sulfamyl group in the 4-turn. The reaction can be carried out in the absence of a natriuretic effect, while the potassium release or preferably in the presence of the solution precipitation is not promoted to the same extent. In agents, such as an ether, e.g. paradioxan patients with fluid and coke salt retention or diethylene glycol dimethyl ether, or a pre- due to diseases of the heart, liver (cymamide, e.g. dimethylformamide, in the case of rum-rose) or the kidneys (nephrosis), causes pre- temperature or elevated temperature, and the bond a therapeutically desired transport at normal or elevated pressure, or in of the liquid and coke salt excretion without the presence of an inert gas, such as nitrogen, there is at the same time some danger of a ca- Depending on the reaction conditions, lium depletion. The doses that are neces- the new compound in free form or dige for such an effect by peroral ad- in the form of its salts. Obtained metal salts administration is on average on the milk can, e.g. transferred to the free compound between 25 and 100 mg per day. The new connected reaction with aqueous, acidic agents, such as these are also able to lower the arterial as mineral acid, e.g. halogen hydrogen or high pressures, above all when acid is given, e.g. hydrochloric or sulfuric acid. These, together with other blood pressure-lowering agents, can again be transferred to the metal salts, such agents. as alkali metal salts in treatment e.g.
Den nye forbindelse fåes når man om- eks. med metallhydroksyd, slik som na-setter 5-klor-2,4-disulfamyl-anilin eller et trium eller kaliumhydroksyd, i et oppløs-salt av dette med formaldehyd. Fortrinns- ningsmiddel, slik som en alkohol, f. eks. vis foretar man reaksjonen i nærvær av metanol, eller etanol, eller i vann <og på-en syre, slik som >en mineralsyre, f. eks. en følgende avdampning av <oppiøsningsmidlet halogenhydrogensyre, f. eks. saltsyre eller eller ved å la den fri forbindelse reagere bromhydrogensyre, eller svovelsyre, even- i en eter, slik som paradioksan eller di-tuelt i vannfri form. Formaldehydet kan metylenglykoldimetyleter med et alkali-også anvendes i form av et av sine poly- metallhydrid eller amid, f. eks. natrium-mere, eller reaksjonsdyktige funksjonelle eller kaliumhydrid eller amid. The new connection is obtained when one re- e.g. with metal hydroxide, such as sodium 5-chloro-2,4-disulfamyl-aniline or a triium or potassium hydroxide, in a soluble salt thereof with formaldehyde. Preferential agent, such as an alcohol, e.g. method, the reaction is carried out in the presence of methanol, or ethanol, or in water <and on-an acid, such as >a mineral acid, e.g. a subsequent evaporation of the <solvent halogen hydrogen acid, e.g. hydrochloric acid or or by allowing the free compound to react hydrobromic acid, or sulfuric acid, possibly in an ether, such as paradioxane or di-tually in anhydrous form. The formaldehyde can methylene glycol dimethyl ether with an alkali also be used in the form of one of its poly- metal hydride or amide, e.g. sodium mer, or reactive functional or potassium hydride or amide.
derivater, f. eks. paraformaldehyd, triok- Oppfinnelsen beskrives nærmere i de san eller heksametylentetramin eller et følgende eksempler. Temperaturene er an-acetal, f. eks. dimetoksymetan eller dietok- gitt i Celsiusgrader, derivatives, e.g. paraformaldehyde, trioc- The invention is described in more detail in the san or hexamethylenetetramine or a following examples. The temperatures are an-acetal, e.g. dimethoxymethane or dietoc- given in degrees Celsius,
symetan. Reaksjonen utføres i første rekke symethane. The reaction is carried out first
Eksempel 1. Example 1.
Man oppvarmer en blanding 2,9 g 5-klor-2,4-disulfamyl-anilin i 15 cm<3> vannfri dietylenglykoldimetyleter, 0,5 cm<3> ed-diksyreetylester inneholdende 109,5 g klor-hydrogensyre pr. 1000 cm3, og 0,33 g para-formaldehyd til 80—90° C, og holder 1 ti-me ved denne temperatur. Man avkjøler til romtemperatur, inndamper reaksjons-blandingen under forminsket trykk til 1/3 av dens volum og fortynner med vann. Det utkrystalliserte produkt frafiltreres og omkrystalliseres fra vann. Man får således 6-klor-7-sulfamyl-3,4-dihydro-l,2,4-benzo-tiadiazin-l,l-dioksyd, som smelter ved 266 —268° C. A mixture of 2.9 g of 5-chloro-2,4-disulfamyl-aniline in 15 cm<3> of anhydrous diethylene glycol dimethyl ether, 0.5 cm<3> of acetic acid ethyl ester containing 109.5 g of hydrochloric acid per 1000 cm3, and 0.33 g of para-formaldehyde to 80-90° C, and keep for 1 hour at this temperature. Cool to room temperature, evaporate the reaction mixture under reduced pressure to 1/3 of its volume and dilute with water. The crystallized product is filtered off and recrystallized from water. Thus, 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzo-thiadiazine-1,1-dioxide is obtained, which melts at 266-268°C.
Erstatter man i ovenstående eksempel paraformaldehyd med 0,84 g 1,1-dimetoksymetan og forøvrig går frem som beskrevet ovenfor, får man den tilsvarende forbindelse. If you replace paraformaldehyde in the above example with 0.84 g of 1,1-dimethoxymethane and otherwise proceed as described above, you get the corresponding compound.
Eksempel 2. Example 2.
En blanding av 2,9 g 5-klor-2,4-disulfa-mylanilin i 15 cm<3> dietylenglykol-dimetyleter, 0,8 cm<3> av en 37 pst.ig vandig for-maldehydoppløsning (0,3 g formaldehyd) og 0,5 cm3 av en mettet saltsyre-eddiksyre-etylesteroppløsning oppvarmes 1 time til 80—90° C. Etter inndampning under forminsket trykk og tilsetning av vann, krystalliserer 6-klor-7-sulfamyl-3,4-dihydro-l,2,4-benzotidiazin-l,l-dioksyd. Det omkrystalliseres fra vann og smelter ved 271— 275° C. A mixture of 2.9 g of 5-chloro-2,4-disulfa-mylaniline in 15 cm<3> of diethylene glycol dimethyl ether, 0.8 cm<3> of a 37% aqueous formaldehyde solution (0.3 g formaldehyde) and 0.5 cm3 of a saturated hydrochloric acid-acetic acid-ethyl ester solution are heated for 1 hour to 80-90° C. After evaporation under reduced pressure and addition of water, 6-chloro-7-sulfamyl-3,4-dihydro- 1,2,4-benzothidiazine-1,1-dioxide. It recrystallizes from water and melts at 271-275°C.
Eksempel 3. Example 3.
En blanding av 2,9 g 5-klor-2,4-disul-famylanilin, 0,3 paraformaldehyd og 15 cm<3 >dietylenglykol-dimetyleter oppvarmes 1 time til 80—90° C. Man inndamper reak-sjonsblandingen under forminsket trykk, tilsetter vann, hvoretter 6-klor-sul'famyl-3,4-dihy dro-1,2,4-benzotiadiazin-1,1 -oksyd krystalliserer langsomt. Det frafiltreres og omkrystalliseres fra vann. En blandings-prøve med det ifølge eksempel 1 erholdte produkt begynner å smelte ved 263° C. A mixture of 2.9 g of 5-chloro-2,4-disul-familaniline, 0.3 paraformaldehyde and 15 cm<3 >diethylene glycol dimethyl ether is heated for 1 hour to 80-90° C. The reaction mixture is evaporated under reduced pressure , add water, after which 6-chloro-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-oxide crystallizes slowly. It is filtered off and recrystallized from water. A mixture sample with the product obtained according to example 1 starts to melt at 263°C.
Eksempel 4. Example 4.
En blanding av 5,9 g 5-klor-2,4-disulfa-mylanilin i 40 cm<3> etanol (90 pst.s) inneholdende 1 tablett fast natriumhydroksyd, behandles med 1,6 cm<3> vandig formaldehyd (37 pst.ig), og oppvarmes 1 time på damp-bad. Etter avkjøling og nøytralisering med 2-normal vandig saltsyre utkrystalliserer 6-klor-7-sulfamyl-3,4-dih'ydro-l,2,4-benzotia-diazin-l,l-dioksyd. Det omkrystalliseres fra vann og smelter ved 272—275° C. A mixture of 5.9 g of 5-chloro-2,4-disulfa-mylaniline in 40 cm<3> of ethanol (90 percent.s) containing 1 tablet of solid sodium hydroxide is treated with 1.6 cm<3> of aqueous formaldehyde (37 pst.ig), and heated for 1 hour in a steam bath. After cooling and neutralization with 2-normal aqueous hydrochloric acid, 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothia-diazine-1,1-dioxide crystallizes. It recrystallizes from water and melts at 272-275°C.
Man inndamper moderluten og tilsetter vann, hvoretter det fåes en annen por-sjon 6-klor-7-sulfamyl-3,4-dihydro-l,2,4-benzotiadiazin-l,l-dioksyd. Etter omkry-stallisasjon fra vann, smelter det ved 272— 275° C. En blandingssmeltepunktsprøve med det ifølge eksempel 1 erholdte produkt viser ingen depresjon. The mother liquor is evaporated and water is added, after which another portion of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide is obtained. After recrystallization from water, it melts at 272-275° C. A mixture melting point test with the product obtained according to example 1 shows no depression.
I stedet for etanol kan det også anvendes andre lavere alkanoler, slik som metanol, etanol, isopropanol eller n-butanol som oppløsningsmiddel. Også andre alkali-metallhydroksyder, slik som litium- eller kaliumhydroksyd eller andre basiske kon-densasjonsmidler kan anvendes. Instead of ethanol, other lower alkanols can also be used, such as methanol, ethanol, isopropanol or n-butanol as solvent. Other alkali metal hydroxides, such as lithium or potassium hydroxide or other basic condensing agents can also be used.
Natriumsaltet av denne forbindelse får man ved inndampning av en oppløsning av 6-klor-7-sulfamyl-3,4-dihydro-l,2,4-benzo-tiadiazin-l,l-dioksyd i en ekvimolar mengde av en vandig natriumhydroksydoppløs-ning. The sodium salt of this compound is obtained by evaporation of a solution of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzo-thiadiazine-1,1-dioxide in an equimolar amount of an aqueous sodium hydroxide solution. nothing.
1. Fremgangsmåte til fremstilling av 6-klor-7-sulfamyl-3,4-dihydro-l,2,4-benzo-tiadiazin-l,l-dioksyd som har diuretisk og natriuretisk virkning og har formelen 1. Process for the production of 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzo-thiadiazine-1,1-dioxide which has diuretic and natriuretic action and has the formula
og dens salter, karakterisert ved at man omsetter 5-klor-2,4-disulfamyl-anilin eller et salt av dette med formaldehyd og om ønskes, overfører erholdte salter til den fri forbindelse eller overfører den fri forbindelse til dens salter. 2. Fremgangsmåte ifølge påstand 1, karakterisert ved at man anvender formaldehydet i form av et reaksjonsdyktig funksjonelt derivat, slik som et acetal eller i form av en av sine polymere, slik som para-formaldehyd. 3. Fremgangsmåte ifølge påstand 1—2, karakterisert ved at man omsetter 5-klor-2,4-disulfamylanilin med formaldehyd i nærvær av en syre, fortrinnsvis saltsyre. and its salts, characterized by reacting 5-chloro-2,4-disulfamyl-aniline or a salt thereof with formaldehyde and, if desired, transferring the obtained salts to the free compound or transferring the free compound to its salts. 2. Method according to claim 1, characterized in that formaldehyde is used in the form of a reactive functional derivative, such as an acetal or in the form of one of its polymers, such as para-formaldehyde. 3. Process according to claims 1-2, characterized in that 5-chloro-2,4-disulfamylaniline is reacted with formaldehyde in the presence of an acid, preferably hydrochloric acid.
Claims (9)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1695670 | 1970-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO130048B true NO130048B (en) | 1974-07-01 |
Family
ID=20303048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO04610/71*[A NO130048B (en) | 1970-12-15 | 1971-12-14 |
Country Status (18)
Country | Link |
---|---|
JP (1) | JPS5417766B1 (en) |
AT (1) | AT318458B (en) |
BE (1) | BE775319A (en) |
CA (1) | CA946593A (en) |
CH (1) | CH537263A (en) |
CS (1) | CS159298B2 (en) |
DE (1) | DE2152124B2 (en) |
DK (1) | DK126976B (en) |
ES (2) | ES398005A1 (en) |
FI (1) | FI52676C (en) |
FR (1) | FR2118494A5 (en) |
GB (1) | GB1337298A (en) |
HU (1) | HU171636B (en) |
IL (1) | IL38322A (en) |
IT (1) | IT940056B (en) |
NL (1) | NL158424B (en) |
NO (1) | NO130048B (en) |
ZA (1) | ZA718140B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2128654A (en) * | 1982-10-12 | 1984-05-02 | Balfour Beatty Ltd | Wall panel |
IT1195098B (en) * | 1986-07-11 | 1988-10-12 | Russo A & C Sas | PLANT FOR THE PRODUCTION ON TRACK OF ALVEOLAR PANELS IN REINFORCED CONCRETE OR PARTIALLY PRE-COMPRESSED OR WITH SLOW REINFORCEMENT EXTENDED TO THE LOWER AND UPPER SURFACES AND TO THE RIBS AND DERIVED PRODUCT |
FR2671119B1 (en) * | 1990-12-28 | 1993-04-09 | Saret France | CONCRETE CONSTRUCTION ELEMENTS, PRE-STRESSED, OF THE PRELABS TYPE, INSTALLATION AND METHOD FOR THEIR MANUFACTURE. |
ES2155293B1 (en) * | 1997-02-04 | 2001-12-16 | Extremadura 2000 De Estructura | MANUFACTURING PROCEDURE OF PRETENSED PLATES TYPE PI BY EXTRUSION. |
-
1971
- 1971-10-18 CA CA125,319A patent/CA946593A/en not_active Expired
- 1971-10-19 GB GB4847071A patent/GB1337298A/en not_active Expired
- 1971-10-19 AT AT902971A patent/AT318458B/en not_active IP Right Cessation
- 1971-10-20 DE DE2152124A patent/DE2152124B2/en active Granted
- 1971-10-27 IT IT70522/71A patent/IT940056B/en active
- 1971-10-29 DK DK529171AA patent/DK126976B/en unknown
- 1971-10-30 CH CH1574271A patent/CH537263A/en not_active IP Right Cessation
- 1971-11-03 FI FI713135A patent/FI52676C/en active
- 1971-11-12 BE BE775319A patent/BE775319A/en unknown
- 1971-11-14 NL NL7115634.A patent/NL158424B/en unknown
- 1971-11-17 JP JP9157371A patent/JPS5417766B1/ja active Pending
- 1971-12-01 FR FR7143960A patent/FR2118494A5/fr not_active Expired
- 1971-12-06 ZA ZA718140A patent/ZA718140B/en unknown
- 1971-12-08 IL IL38322A patent/IL38322A/en unknown
- 1971-12-10 HU HU71NI00000143A patent/HU171636B/en unknown
- 1971-12-14 NO NO04610/71*[A patent/NO130048B/no unknown
- 1971-12-14 CS CS869071A patent/CS159298B2/cs unknown
- 1971-12-15 ES ES398005A patent/ES398005A1/en not_active Expired
- 1971-12-15 ES ES398004A patent/ES398004A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FI52676B (en) | 1977-08-01 |
HU171636B (en) | 1978-02-28 |
ES398004A1 (en) | 1974-07-01 |
DE2152124A1 (en) | 1972-07-20 |
CS159298B2 (en) | 1974-12-27 |
IL38322A (en) | 1974-12-31 |
SU438162A3 (en) | 1974-07-30 |
NL158424B (en) | 1978-11-15 |
BE775319A (en) | 1972-03-01 |
DE2152124C3 (en) | 1974-09-19 |
ES398005A1 (en) | 1974-07-01 |
IL38322A0 (en) | 1972-02-29 |
DE2152124B2 (en) | 1974-02-14 |
FI52676C (en) | 1977-12-01 |
FR2118494A5 (en) | 1972-07-28 |
ZA718140B (en) | 1972-08-30 |
AT318458B (en) | 1974-10-25 |
NL7115634A (en) | 1972-06-19 |
JPS5417766B1 (en) | 1979-07-03 |
GB1337298A (en) | 1973-11-14 |
CH537263A (en) | 1973-05-31 |
AU3490371A (en) | 1973-05-03 |
CA946593A (en) | 1974-05-07 |
IT940056B (en) | 1973-02-10 |
DK126976B (en) | 1973-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS626546B2 (en) | ||
DK145676B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF OXOAL CHOYDIALYCHYLXANTHINES | |
EP2464638A1 (en) | Lenalidomide salts | |
EP1194415B1 (en) | Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for their preparation | |
NO130048B (en) | ||
JPH0150698B2 (en) | ||
NO138338B (en) | PROCEDURE FOR THE PREPARATION OF WOODBOARD PLATES WITH CONDENSATION RESINS AS BINDER | |
NO138408B (en) | COMPOUND FOR USE AS A STARTING MATERIAL FOR THE PREPARATION OF 1- (4-METZYL-6-METHOXY-2-PYRIMIDINYL) -3-METHYL-5-METHOXYPYRAZOLE, AND PROCEDURE FOR PREPARING | |
SU488408A3 (en) | Method for preparing substituted 3- (2-4phenyl-1-piperazinyl-ethyl) -indolines or their salts, or their quaternary ammonium salts | |
PT100097A (en) | NEW THERAPEUTIC AGENTS CONSTITUTED BY QUINOLINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | |
NO763876L (en) | ||
NO137093B (en) | PROCEDURES FOR THE PREPARATION OF 2,4-DIAMINO-5-BENZYLPYRIMIDINES | |
Adams et al. | The Reaction of 2-Aminopyridine with α-Halo Ketones | |
NO150553B (en) | INFLATABLE BATH | |
EP2547681B1 (en) | Tosylate salt of cyclopropanecarboxylic acid 4-(6-chloro-3-metyhl-4,10-dihydro-3h-2,3,4,9-tetrabenzo[f]azulene-9-carbonyl)-2-fluorobenzylamide | |
US2597445A (en) | Nu-alkylamino-methyl-phenyl-propane and method of preparing same | |
NO125530B (en) | ||
US2654753A (en) | 2-sulfanilamido-5-aminopyrimidine and salts thereof | |
NO164934B (en) | PROCEDURE FOR MEASURING PRESSURE BY PERFORMING A DRILL IN A DRILL. | |
NO137900B (en) | ANALOGICAL PROCEDURES FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE, BASIC SUBSTITUTED THEOPHYLLIN DERIVATIVES | |
US2741615A (en) | N-substituted dihydrodesoxynorcodeine compounds | |
Roe et al. | The Reaction of Ketene with 2-Nitro-4-chlorophenylsulfenyl Chloride and Other Organic Halogen Compounds | |
Cox et al. | Arylsulfonyl Ureas | |
Phillips et al. | Nitrogen-substituted Chloroalkylamines1 | |
PL49637B1 (en) |